

26 November 2024

INOVIQ receives \$1m R&D Tax Incentive Refund

INOVIQ Limited (ASX:IIQ) (**INOVIQ** or the **Company**) is pleased to announce that it has received a \$1.018m Research & Development (R&D) Tax Incentive refund relating to its FY24 R&D activities.

The Australian Government's R&D Tax Incentive program provides companies with a 43.5% refundable tax offset for eligible R&D activities. INOVIQ incurred \$2.7m on R&D activities in FY24 and was able to claim the refund on eligible expenditure which excluded certain overseas based expenditure.

Authorised for release by Company Secretary, Mark Edwards.

FURTHER INFORMATION

Dr Leearne Hinch
Chief Executive Officer
E lhinch@inoviq.com
M +61 400 414 416

David Williams
Chairman
E dwilliams@kidder.com.au
M +61 414 383 593

ABOUT INOVIQ LTD

INOVIQ Ltd (ASX:IIQ) is a biotechnology company developing next-generation diagnostics and therapeutics for cancer. INOVIQ has commercialised its fast, efficient and scalable EXO-NET exosome isolation technology for biomarker discovery and diagnostics development, and the hTERT test as an adjunct test for bladder cancer. The company is advancing clinical-stage diagnostics for detection and monitoring of ovarian and breast cancers, and early-stage exosome therapeutics for solid tumours. For more information on INOVIQ, visit www.inoviq.com.

For personal use only